According to Oral Vaccine Market Report, Elimination of needles in the vaccination process and their
safe & cost effective nature are driving the oral vaccines market remarkably. The rising prevalence of
infectious diseases in developing countries, resistance to existing vaccines, and bioterrorism are some of
the factors expected to push the market from 2019 to 2023.
Regionally, North America captured a prominent market share owing to the high purchasing power of
the region’s population to afford costly vaccines and the periodical mass immunization programs held by
the government. However, Asia Pacific is expected to witness a significant CAGR on account of the rising
incidence of HIV and influenza in developing countries.
Oral Vaccine Market Covers the Table of Contents With Segments, Key Players And Region. Based on
Product Type, Oral Vaccine Market is sub segmented into Rotavirus Vaccine, Cholera Vaccine, Oral Polio
Vaccine. On the Basis of Application, Market is sub segmented into Public and Private.
Major Players profiled in the Oral Vaccine Market report incorporate: Merck, GSK, Sanofi, Lanzhou
Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol, PaxVax, Vabiotech, Tiantan Biological,
EuBiologics, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals
Top Industry for Oral Vaccine Market News
Merck
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results
from a Phase 2 trial (NCT02982972) evaluating the safety, tolerability and immunogenicity of V114, the
company’s investigational 15-valent pneumococcal conjugate vaccine, as compared to the currently
available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age. In the
study, designated V114-008, V114 met its primary endpoint by demonstrating noninferiority for the 13
serotypes contained in both vaccines. V114 also induced an immune response in infants for two
additional disease-causing serotypes, 22F and 33F, which are not contained in PCV13. In January 2019,
V114 received a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA)
for the prevention of invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric
patients 6 weeks to 18 years of age. The FDA’s decision was informed in part by immunogenicity data
from this Phase 2 study, V114-008, and the Phase 1/2 V114-005 study in healthy adults and infants.
Results of the V114-008 study were presented during an oral session at the 37th Annual Meeting of the
European Society for Paediatric Infectious Diseases (ESPID) in Ljubljana, Slovenia, and reinforce
continued progression of Phase 3 clinical studies with V114.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/167443 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Oral Vaccine in these regions, from 2014 to 2023 (forecast), covering: North
America, Europe, Asia Pacific, Middle East & Africa and South America.